Cross-priming by temozolomide enhances antitumor immunity of dendritic cell vaccination in murine brain tumor model

Vaccine. 2007 Apr 30;25(17):3485-91. doi: 10.1016/j.vaccine.2006.12.060. Epub 2007 Jan 17.

Abstract

Although chemotherapy remains among the best treatment options for most cancers, adjuvant therapies such as dendritic cell (DC)-based immunotherapy have been added to treatment protocols to destroy residual tumor cells. IFN-gamma secreting T cells specific for survivin was found after temozolomide (TMZ) treatment in C57BL/6 mice intracranial (i.c.) inoculated with GL26 cells. Furthermore, combination treatment with low-dose TMZ (2.5mg/kg/day, i.p.) chemotherapy followed by vaccination with survivin RNA-transfected DCs (1 x 10(6)cells/mouse, s.c.) enhanced T cells responses specific for survivin and improved survival rate compared with DC vaccination alone or TMZ treatment alone in tumor inoculated mice. However, these enhancements of T cells responses by TMZ treatment were not observed in mice without tumor inoculation. These results suggested that cross-priming by TMZ may enhance antitumor immunity of DC vaccination in murine brain tumor model.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents, Alkylating / pharmacology*
  • Brain Neoplasms / immunology
  • Brain Neoplasms / therapy*
  • Cross-Priming*
  • Dacarbazine / analogs & derivatives*
  • Dacarbazine / pharmacology
  • Dendritic Cells / immunology*
  • Disease Models, Animal
  • Female
  • Inhibitor of Apoptosis Proteins
  • Lymphocyte Activation
  • Mice
  • Mice, Inbred C57BL
  • Microtubule-Associated Proteins / physiology
  • Repressor Proteins
  • Survivin
  • Temozolomide
  • Transfection
  • Vaccination*

Substances

  • Antineoplastic Agents, Alkylating
  • Birc5 protein, mouse
  • Inhibitor of Apoptosis Proteins
  • Microtubule-Associated Proteins
  • Repressor Proteins
  • Survivin
  • Dacarbazine
  • Temozolomide